GLP-1 receptor agonists are rapidly evolving from diabetes and weight-loss drugs into broader cardiometabolic therapies, with emerging anti-inflammatory and potential neuroprotective benefits.
But their expansion comes with a clear clinical constraint: gastrointestinal tolerability. From nausea and delayed gastric emptying to higher discontinuation rates, GI side effects remain the primary barrier to sustained use—shaping both patient adherence and procedural considerations in practice.
The shift is clear:
GLP-1s are no longer niche therapies—but managing their GI impact is becoming central to their real-world success.